BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 16387106)

  • 41. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CMV hepatitis after liver transplantation: incidence, clinical course, and long-term follow-up.
    Seehofer D; Rayes N; Tullius SG; Schmidt CA; Neumann UP; Radke C; Settmacher U; Müller AR; Steinmüller T; Neuhaus P
    Liver Transpl; 2002 Dec; 8(12):1138-46. PubMed ID: 12474153
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Late cytomegalovirus disease with atypical presentation in renal transplant patients: case reports.
    Boobes Y; Al Hakim M; Dastoor H; Bernieh B; Abdulkhalik S
    Transplant Proc; 2004; 36(6):1841-3. PubMed ID: 15350493
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen.
    Thomas LD; Milstone AP; Miller GG; Loyd JE; Stephen Dummer J
    Clin Transplant; 2009; 23(4):476-83. PubMed ID: 19453645
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
    Bataille S; Moal V; Gaudart J; Indreies M; Purgus R; Dussol B; Zandotti C; Berland Y; Vacher-Coponat H
    Transpl Infect Dis; 2010 Dec; 12(6):480-8. PubMed ID: 20629971
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis.
    Rayes N; Seehofer D; Kahl A; Kokott S; Pratschke J; Frei U; Neuhaus P
    Transpl Int; 2007 Nov; 20(11):974-81. PubMed ID: 17680782
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation.
    Sarmiento E; Lanio N; Gallego A; Rodriguez-Molina J; Navarro J; Fernandez-Yañez J; Palomo J; Rodríguez-Hernández C; Ruiz M; Alonso R; Fernandez-Cruz E; Carbone J
    Int Immunopharmacol; 2009 Jun; 9(6):649-52. PubMed ID: 18940269
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants.
    Manuel O; Pang XL; Humar A; Kumar D; Doucette K; Preiksaitis JK
    J Infect Dis; 2009 Jun; 199(11):1621-8. PubMed ID: 19385736
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy.
    De Santo LS; Romano G; Mastroianni C; Roberta C; Della Corte A; Amarelli C; Maiello C; Giannolo B; Marra C; Ragone E; Grimaldi M; Utili R; Scardone M; Cotrufo M
    Transplant Proc; 2005; 37(6):2684-7. PubMed ID: 16182784
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of cytomegalovirus antigenemia titer on the efficacy of preemptive therapy for the prevention of cytomegalovirus disease after kidney transplantation.
    Jung GO; Kim SJ; Choi GS; Moon JI; Kim JM; Sin MJ; Kim EY; Kwon CH; Joh JW; Lee SK
    Transplant Proc; 2010 Apr; 42(3):804-10. PubMed ID: 20430177
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytomegalovirus replication and "herpesvirus burden" as risk factor of cardiovascular events in the first year after renal transplantation.
    Gómez E; Laurés A; Baltar JM; Melón S; Díez B; de Oña M
    Transplant Proc; 2005 Nov; 37(9):3760-3. PubMed ID: 16386530
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
    Slifkin M; Ruthazer R; Freeman R; Bloom J; Fitzmaurice S; Fairchild R; Angelis M; Cooper J; Barefoot L; Rohrer R; Snydman DR
    Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changing impact of cytomegalovirus in liver transplantation -- a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis.
    Seehofer D; Rayes N; Neumann UP; Meisel H; Oettle H; Nüssler NC; Jonas S; Langrehr JM; Neuhaus P
    Transpl Int; 2005 Aug; 18(8):941-8. PubMed ID: 16008744
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incidence and predictive factors for cytomegalovirus infection in renal transplant recipients.
    Corona-Nakamura AL; Monteón-Ramos FJ; Troyo-Sanromán R; Arias-Merino MJ; Anaya-Prado R
    Transplant Proc; 2009; 41(6):2412-5. PubMed ID: 19715936
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oral valgancyclovir versus intravenous gancyclovir for cytomegalovirus prophylaxis in kidney transplant recipients.
    Said T; Nampoory MR; Pacsa AS; Essa S; Madi N; Fahim N; Abraham M; Nair P; Al-Otaibi T; Halim MA; Johny KV; Al-Mousawi M
    Transplant Proc; 2007 May; 39(4):997-9. PubMed ID: 17524873
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.
    Ruttmann E; Geltner C; Bucher B; Ulmer H; Höfer D; Hangler HB; Semsroth S; Margreiter R; Laufer G; Müller LC
    Transplantation; 2006 May; 81(10):1415-20. PubMed ID: 16732179
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation.
    Macdonald PS; Keogh AM; Marshman D; Richens D; Harvison A; Kaan AM; Spratt PM
    J Heart Lung Transplant; 1995; 14(1 Pt 1):32-8. PubMed ID: 7727473
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients.
    Haririan A; Morawski K; West MS; El-Amm JM; Doshi MD; Cincotta E; Alangaden GJ; Chandrasekar P; Gruber SA
    Clin Transplant; 2007; 21(4):466-71. PubMed ID: 17645705
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytomegalovirus infection after renal transplantation: selective prophylaxis and treatment.
    Pascual J; Alarcón MC; Marcén R; Burgos FJ; Tato A; Tenorio MT; Liaño F; Ortuño J
    Transplant Proc; 2003 Aug; 35(5):1756-7. PubMed ID: 12962783
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of ganciclovir prophylaxis on citomegalovirus, human herpesvirus 6, and human herpesvirus 7 viremia in renal transplant recipients.
    Galarraga MC; Gomez E; de Oña M; Rodriguez A; Laures A; Boga JA; Melon S
    Transplant Proc; 2005 Jun; 37(5):2124-6. PubMed ID: 15964357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.